Lead
U.S. influenza activity is low at the start of the season, but CDC data posted Friday shows a new H3N2 subclade — a K variant — is now driving most infections, prompting concern among health experts. Early United Kingdom analyses indicate this season’s vaccines may offer at least partial protection against the new variant, though full effectiveness remains uncertain. Public-health specialists warn that disappointing vaccination coverage and gaps in surveillance could allow a severe wave like last winter’s, when flu contributed to more than 18,000 deaths. Officials are urging timely vaccination as travel and gatherings increase in the coming months.
Key Takeaways
- CDC data posted Friday shows overall U.S. flu activity is currently low; only Louisiana reports moderate activity so far.
- Most early infections have been type A H3N2; over half of those sequenced are the new K subclade that differs from the vaccine strain.
- Preliminary U.K. analyses suggest current vaccines provide at least partial protection against the K subclade; definitive effectiveness estimates are pending.
- Last winter’s season produced the highest overall hospitalization rate since the H1N1 pandemic 15 years ago and more than 18,000 deaths nationwide.
- Vaccination metrics are mixed: CDC survey data show childhood flu shots at about 34% and adult flu shots near 37% so far; IQVIA reports over 2 million fewer pharmacy flu doses dispensed through October versus last year.
- Up-to-date COVID-19 vaccination coverage has declined (about 6% of children, 14% of adults), each roughly 3 percentage points below levels at the same point last fall, per CDC survey data posted Friday.
- Data collection and reporting were disrupted by a recent government shutdown, limiting early-season surveillance when infections were beginning to rise.
Background
H3N2 has historically been associated with higher hospitalization and death rates, particularly among older adults, and was the dominant strain in the severe season last year. During the 2023–24 season, flu was listed as an underlying or contributing cause in more than 18,000 deaths; one seven-day period early in the year recorded more than 1,800 deaths. That severity has heightened attention on vaccine coverage and strain matching in planning for the 2024–25 season.
Vaccine formulation is updated annually to match circulating strains, but the influenza virus continually evolves. Public-health agencies monitor genetic changes and early clinical data to estimate vaccine effectiveness; those assessments can take several weeks to months once a new variant emerges. Surveillance systems that feed data into these assessments rely on steady reporting from state and federal systems.
This year, surveillance and outreach have been complicated by two factors: an interruption in CDC reporting caused by a government shutdown just as respiratory infections were rising, and leadership changes at the agency that have altered federal communications about vaccination campaigns. Both issues affect how quickly officials can detect and respond to shifts in virus behavior and vaccine uptake.
Main Event
CDC’s posting on Friday shows low national activity overall, with Louisiana the only state reporting moderate flu activity. The agency’s tracker indicates that most lab-confirmed infections reported so far are occurring in children, a pattern that often precedes broader community spread. CDC surveillance lead Alicia Budd noted the child-centered distribution of cases as a key early warning sign.
Genetic sequencing reported to CDC finds that the majority of recent infections are type A H3N2, and that more than half of those belong to a K subclade that differs from the H3N2 strain used in this season’s vaccine. That divergence prompted an early analysis from U.K. researchers suggesting the current shots still provide partial protection — enough, experts say, to reduce severity even if infections still occur.
Vaccination coverage shows a mixed picture. CDC survey data posted Friday indicate roughly 34% of children had received a flu vaccine by this point in the season, similar to last year, and adult self-reported flu vaccination stood at about 37%, a modest increase. However, IQVIA pharmacy-dispensing data show over two million fewer flu doses were administered through U.S. pharmacies by the end of October versus the same point last year, suggesting distribution and site-of-delivery shifts.
Health officials warn that flu seasons usually peak between December and February and that travel and indoor gatherings for holidays can accelerate spread. Clinicians and public-health leaders emphasize that any vaccine-conferred reduction in severity can meaningfully lower hospitalizations and deaths, particularly among high-risk groups.
Analysis & Implications
The emergence of a K subclade within H3N2 raises two central questions for the 2024–25 season: how well current vaccines will blunt disease and whether population immunity is sufficient to prevent high hospitalization numbers. Early U.K. signals of partial protection are encouraging, but formal vaccine effectiveness estimates require more epidemiologic data from diverse settings.
Vaccine uptake matters more when a strain is partially matching. Even imperfect vaccine effectiveness can reduce severe outcomes, ICU admissions and deaths, which is crucial given last winter’s heavy toll. If adult and pediatric vaccination rates slip — or remain uneven across regions and communities — the healthcare system could again face heavy seasonal pressure.
Data gaps caused by the recent reporting interruption complicate real-time situational awareness. Delays in sequencing, case counts and hospital reporting can slow detection of accelerating activity or changes in age patterns, undermining timely public-health responses and targeted messaging to at-risk populations.
Policy and communication also matter. Changes in federal leadership and shifts in public messaging can influence public confidence. Officials must balance transparency about uncertainty with clear guidance on vaccination as the primary preventive tool available now to reduce severe illness.
Comparison & Data
| Metric | Last major season (2023–24) | Early 2024–25 (as reported) |
|---|---|---|
| Flu-linked deaths (season) | >18,000 | Data accumulating |
| Peak one-week deaths | >1,800 | Not yet observed |
| Dominant virus | H3N2 | H3N2 (K subclade predominating) |
| Child flu vaccination rate (by early season) | ~34% (same point last fall) | ~34% |
| Adult flu vaccination rate (survey) | ~34% (prior) | ~37% (survey) |
| Pharmacy doses through Oct (IQVIA) | Baseline (prior year) | ~2 million fewer doses dispensed |
These numbers show that although early-season activity is low, viral evolution (K subclade) and mixed vaccination signals leave meaningful uncertainty about the coming peak months. Surveillance and rapid vaccine-effectiveness studies will determine whether the vaccine substantially blunts severe outcomes.
Reactions & Quotes
Most of the reported infections have been in children.
Alicia Budd, CDC (surveillance lead)
CDC surveillance staff emphasized the early concentration of cases in children as an important marker that can precede broader community spread and escalate demand for pediatric care.
I think we’re going to see a really severe season.
Asefeh Faraz Covelli, George Washington University School of Nursing
Covelli compared current early indicators to last winter’s severe season and urged preparatory action by hospitals and public-health programs to avoid being overwhelmed.
This is the ideal time to get vaccinated.
Asefeh Faraz Covelli, George Washington University School of Nursing
Public-health advocates used that message to stress that even partial vaccine protection can reduce severe disease and lessen strain on healthcare systems during the December–February peak.
Unconfirmed
- Precise vaccine effectiveness against the K subclade is not yet confirmed; U.K. analyses are preliminary and broader studies are pending.
- The full impact of the recent reporting interruption on national surveillance completeness has not been fully quantified.
- The degree to which leadership and messaging changes at federal agencies will affect vaccine confidence and uptake is uncertain and subject to evolving public response.
Bottom Line
Early-season U.S. flu activity is low, but the rise of an H3N2 K subclade and mixed signals on vaccination rates create real uncertainty about whether this season could match last winter’s severity. Preliminary data suggesting partial vaccine protection argue for promoting flu shots now, especially for older adults, young children and other high-risk groups.
Stronger, faster surveillance and clear public-health communication are essential in the coming weeks to determine vaccine performance and to direct targeted interventions. Given typical winter peaks from December through February, timely vaccination and continued monitoring remain the most effective immediate tools to reduce hospitalizations and deaths.
Sources
- The Associated Press (news report summarizing CDC data)
- Centers for Disease Control and Prevention (CDC) (official surveillance data and vaccine guidance)
- IQVIA (health-data firm reporting pharmacy vaccine dispensing trends)
- UK Health Security Agency (source of early U.K. analyses of vaccine match and effectiveness)